XML 25 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (5,448) $ (14,282)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1 2
Stock-based compensation 354 382
Noncash interest expense 347
Arbitration settlement expense 1,500
Warrant modification expense 1,627
Change in fair value of equity investment 16 6
Change in fair value of derivative liabilities 6,956
Gain on purchase of warrants (64)
Changes in operating assets and liabilities:    
Trade receivable 191 (175)
Other accounts receivable and prepaid expenses (482) 37
Inventory (2,000) (30)
Trade payables (21) (59)
Other accounts payable and accrued expenses 78 (265)
Deferred revenue (69) (2)
Accrued severance pay, net (2)
Net cash used in operating activities (7,035) (4,367)
Cash flows from investing activities:    
Purchases of fixed assets (3) (3)
Net cash used in investing activities (3) (3)
Cash flows from financing activities:    
Proceeds from sale of common stock, net 2,090
Proceeds from exercise of options 2
Proceeds from exercise of warrants 4,968
Buy back of warrants from investor (388)
Net cash provided by financing activities 2,092 4,580
Effects of currency translation on cash (78) (6)
Net (decrease) increase in cash (5,024) 204
Cash at beginning of period 7,737 7,533
Cash at end of period 2,713 7,737
Supplemental disclosures of cash flow information:    
Cash paid for interest
Cash paid for taxes
Supplemental non-cash financing and investing activities:    
Exchange of common stock into preferred stock 1
Shares issued from exercise of warrants previously classified as derivative liability 2,087
Reclass derivative liability to equity due to increase in authorized shares 8,706
Reclass liability to equity after increase in authorized shares $ 2,257